Loading…
5 companies · GEL, thousands · columns ordered by revenue
| Line item | Neoparmi | Bioparmi | Biopolusi | Inovas | Krokus Pharma |
|---|---|---|---|---|---|
| Total Revenue | 19,189 | 10,150 | 6,488 | 5,010 | 4,156 |
| Total COGS | -12,616 | -4,625 | -2,854 | -1,842 | -1,741 |
| Gross Profit | 6,573 | 5,525 | 3,634 | 3,169 | 2,415 |
| Gross Margin | 34.3% | 54.4% | 56.0% | 63.2% | 58.1% |
| Total Operating Expenses | -6,950 | -6,373 | -1,737 | -336 | -998 |
| EBITDA | -376 | -847 | 1,897 | 2,832 | 1,417 |
| EBITDA Margin | -2.0% | -8.3% | 29.2% | 56.5% | 34.1% |
| Total D&A | -141 | -313 | 0 | -5 | -8 |
| EBIT / Operating Income | -517 | -1,161 | 1,897 | 2,828 | 1,409 |
| Total Interest Income | 21 | — | — | — | — |
| Total Interest Expense | -1 | — | — | -39 | — |
| Total Other Income | -41 | -115 | -365 | -42 | -62 |
| Profit Before Tax | -539 | -1,276 | 1,532 | 2,747 | 1,347 |
| Total Income Tax | -50 | 0 | 0 | 0 | -74 |
| Net Profit / (Loss) | -589 | -1,276 | 1,532 | 2,747 | 1,273 |
| Net Margin | -3.1% | -12.6% | 23.6% | 54.8% | 30.6% |
| Other Comprehensive Income | — | 2,385 | — | — | — |
| Total Comprehensive Income | — | 1,109 | — | — | — |
| Company | Sector | EBITDA margin · FY 2024 | Percentile | Sector n |
|---|---|---|---|---|
| Inovas | Pharma | 56.5% | 100th pct | 110 |
| Krokus Pharma | Pharma | 34.1% | 83rd pct | 110 |
| Biopolusi | Pharma | 29.2% | 74th pct | 110 |
| Neoparmi | Pharma | -2.0% | 12th pct | 110 |
| Bioparmi | Pharma | -8.3% | 5th pct | 110 |
Percentile is within each company's own sector across the whole FY2024 cross-section (1st–100th; higher = larger value). Companies with no sector, or no filing for the year, are not ranked.